# First targeted therapy for Guillain-Barré syndrome nears approval by turning off rogue immune activity

_Published Monday, August 3, 2026 at 8:26 AM EDT · Science · Latest · Tier 2 — Notable_

New Scientist posted on X on Aug. 2 that a treatment turning off the part of the immune system that goes haywire in Guillain-Barré syndrome may be the first targeted therapy approved for the autoimmune condition.

The post links to a New Scientist article about the potential approval. The treatment targets the rogue immune activity underlying the syndrome. No regulatory decision or timeline was disclosed in the post.

## Sources

- [newscientist](https://x.com/newscientist/status/2084046859236991254)

---
Canonical: https://techandbusiness.org/newswire/kMYEjExX5orYZgxm8GSBTm
Published: 2026-08-03T12:26:33.207Z
Story chronology: 2026-08-02T12:00:00.000Z
Retrieved: 2026-11-01T21:05:37.773Z
Publisher: Tech & Business (techandbusiness.org)